Product Description
a neurokinin 1 (NK-1) antagonist for Irritable Bowel Syndrome (IBS) (Sourced from: https://clinicaltrials.gov/ct2/show/NCT00316550)
Mechanisms of Action: NK1 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Avera
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Overactive Bladder|Phobia, Social
Phase 1: Irritable Bowel Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT00316550 |
AV608-107 | P1 |
Terminated |
Irritable Bowel Syndrome |
2007-06-01 |
2019-03-21 |
Treatments |
|
2005-005868-93 |
2005-005868-93 | P2 |
Completed |
Overactive Bladder |
2007-06-18 |
2022-03-12 |
Treatments |
|
NCT00335660 |
AV608-106 | P2 |
Terminated |
Overactive Bladder |
2007-06-01 |
2019-03-21 |
Treatments |
|
NCT00294346 |
AV608-105 | P2 |
Completed |
Phobia, Social |
2006-12-01 |
2019-03-21 |
Recent News Events
Date |
Type |
Title |
|---|